Nuo Therapeutics

The story of Nuo Therapeutics begins in 1998, though under a different name: Informatix Holdings, Inc. The company's focus was on pioneering regenerative biological therapies. Its core product, eventually named Aurix, was a system designed to create a healing gel from a patient's own blood to treat chronic wounds. This technology aimed to harness the body's natural healing abilities. The early years were turbulent. After a 1999 merger and renaming to Autologous Wound Therapy, and another name change to Cytomedix in 2000, the company filed for Chapter 11 bankruptcy in 2001, emerging a year later. A key milestone came in 2014 when Cytomedix raised $37 million and rebranded as Nuo Therapeutics, shifting its focus squarely to the U.S. wound care market and its Aurix system. However, the company's struggles continued. In January 2016, Nuo Therapeutics filed for Chapter 11 bankruptcy again. The following year, in August 2017, the company withdrew its plans for an $11 million initial public offering (IPO), citing market conditions. The company furloughed its employees in 2019 while awaiting a crucial Medicare coverage decision. After receiving a favorable determination, Nuo began restarting commercial activities in late 2021, and in April 2025, it signed a major distribution agreement with medical technology giant Smith+Nephew to market the Aurix system.